Latest News and Press Releases

ALX Oncology Q4 and EOY 2025 earnings press release

If approved, Dupixent would be the first targeted medicine in the EU indicated for children aged 2 to 11 years with CSU inadequately controlled by standard-of-care antihistamine treatment CSU is a...

Regeneron is renewing it's sponsorship of the Science Talent Search for the next 10 years, committing $150 million.

NETHERTON NOW Recognizes Rare Disease Day and Highlights Growing Global Awareness of Netherton Syndrome

MONTRÉAL, 26 févr. 2026 (GLOBE NEWSWIRE) -- Cannara Biotech Inc. (« Cannara », la «Société », « nous » ou « notre ») (TSXV : LOVE) (OTCQX : LOVFF) (FRA : 8CB0), producteur verticalement...

Cannara (LOVE) graduates to the TSX on March 2, 2026, enhancing visibility, liquidity and institutional access; TD Cowen initiated coverage Feb 24

Over 1.1 million total VOQUEZNA® prescriptions filled to date $57.6 million in Q4 net revenues; $175.1 million in FY 2025 net revenues, a 217% increase from FY 2024 Q4 operating expenses of...

PAI-1 Inhibitor (MDI-2517) demonstrates good safety and tolerability profile, with Phase 2 proof-of-concept trial planned for 2026 in patients with metabolic and fibrotic diseaseCarmel Nanthakumar,...

InnoCare announced key clinical development progress, including the completion of patient enrollment of multiple Phase III registrational trials.

The Stock Markets are opening with a strong crosscurrent of AI-powered drug discovery, cross-border biologics distribution, and capital structure resets